Key result
Combined heart and liver transplantation in a patient with homozygous familial hypercholesterolemia decreased total cholesterol by 71% and LDL cholesterol by 79% at 6 months.
Why the study?
Does combined heart and liver transplantation improve lipid profiles in a patient with terminal ischemic heart disease due to homozygous familial hypercholesterolemia?
Case Report (n=1)
Does combined heart and liver transplantation improve lipid profiles in a patient with terminal ischemic heart disease due to homozygous familial hypercholesterolemia?
Combined heart and liver transplantation can dramatically improve lipid profiles in patients with homozygous familial hypercholesterolemia, offering greater reductions than portacaval shunt or plasma exchange.
Hypothesis-generating for combined transplantation in homozygous familial hypercholesterolemia; prospective trials needed before clinical adoption.
Changes in lipids and lipoprotein fractions were studied 6 months after a combined heart and liver transplantation in a patient with terminal ischemic heart disease due to homozygous familial hypercholesterolemia. The double transplant was followed by striking decreases in total and low-density-lipoprotein cholesterol levels (-71% and -79%) and content of apolipoprotein B in the low-density-lipoprotein fraction (-74%). There was also an increase in high-density-lipoprotein cholesterol (+7.8%). These changes are greater than those reported with portacaval shunt or plasma exchange. Liver transplantation may be considered in selected patients with homozygous familial hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Pedro Valdivielso (1988) conducted a case report in Terminal ischemic heart disease due to homozygous familial hypercholesterolemia (n=1). Combined heart and liver transplantation was evaluated on Changes in lipids and lipoprotein fractions. Combined heart and liver transplantation in a patient with homozygous familial hypercholesterolemia decreased total cholesterol by 71% and LDL cholesterol by 79% at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: